左乙拉西坦在中毒性惊厥中的应用
该研究为城市一级创伤中心2010年1月1日至2015年5月31日的回顾性图表复习,通过ICD-9编码筛选同时有中毒诊断、惊厥诊断且接受左乙拉西坦的患者,纳入34例药物诱导性惊厥患者。17例为全面性强直-阵挛发作(TCS),17例为全面性惊厥性癫痫持续状态(GCSE)。GCSE患者中6例在发作期间接受左乙拉西坦,1例给药后立即改善,其余5例惊厥得到控制;11例(65%)在左乙拉西坦治疗后保持无惊厥。TCS患者17例在惊厥控制后接受左乙拉西坦,16例(94%)住院期间无惊厥。未见药物不良反应,27/34例(79%)神经和躯体功能恢复至基线。作者结论认为左乙拉西坦作为二线药物与药物诱导性惊厥控制和预防复发相关,需前瞻性研究证实。
要点
- 34例药物诱导性惊厥患者中,17例GCSE患者有6例在发作期间接受左乙拉西坦,1例给药后立即改善,其余5例惊厥得到控制。
- GCSE患者中11例(65%)在左乙拉西坦治疗后保持无惊厥。
- 17例TCS患者在惊厥控制后接受左乙拉西坦,16例(94%)住院期间无惊厥。
- 研究未发现归因于左乙拉西坦的药物不良反应,27/34例(79%)恢复至基线神经和躯体健康。
- 作者结论认为左乙拉西坦作为二线药物与药物诱导性惊厥控制和预防复发相关,需前瞻性研究证实。
适用人群与场景
- 因药物诱导性惊厥就诊于城市一级创伤中心的患者,纳入基于病史、脑电图结果、血酒精浓度、尿药物筛查和充分记录。
- 排除酒精戒断、缺氧性脑损伤、其他抗癫痫药亚治疗浓度、低血糖和假性惊厥的患者。
处置流程与药物剂量
- GCSE患者中6例在惊厥发作期间接受左乙拉西坦,其中2例还接受了磷苯妥英。
- TCS患者17例在惊厥控制后接受左乙拉西坦。
研究设计与关键结果
- 回顾性图表复习,纳入34例药物诱导性惊厥患者,17例为全面性强直-阵挛发作(TCS),17例为全面性惊厥性癫痫持续状态(GCSE)。
- GCSE患者中6例在发作期间接受左乙拉西坦,1例给药后立即改善,其余5例惊厥得到控制;11例(65%)在左乙拉西坦治疗后保持无惊厥。
- TCS患者17例在惊厥控制后接受左乙拉西坦,16例(94%)住院期间无惊厥。
- 未发现归因于左乙拉西坦的药物不良反应;27/34例(79%)恢复至基线神经和躯体健康,6例有长期后遗症,均非已知左乙拉西坦副作用。
- 鉴定出46种毒物和22种已知致惊厥剂(48%);中位住院时间3.7天(0.4-96),中位住院左乙拉西坦治疗时间1.6天(0-49)。
证据类型、等级与局限
- 证据类型:回顾性图表复习。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为左乙拉西坦作为二线药物与药物诱导性惊厥控制和预防复发相关,且未见明显不良反应。
- 作者指出需前瞻性研究证实这些结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVES: The use of levetiracetam (LEV) in the management of drug-induced seizures has not been systematically investigated. Repetitive and continuous seizures that do not respond to benzodiazepines require second line therapy. Levetiracetam has a unique receptor binding site, rapid absorption, no known cardiac effects at therapeutic doses, and is theoretically a good candidate for use in drug-induced seizures. We evaluate the safety of LEV and its association with seizure cessation in this retrospective chart review of patients who received LEV as a control agent in drug-induced seizures.
METHODS: We identified the medical records of patients presenting to an urban, level 1 trauma center between 1 January 2010 and 31 May 2015 by ICD-9 codes based on the following: (1) a poisoning diagnosis, (2) a seizure diagnosis, and (3) administration of LEV. We included patients with a drug-induced seizure based on history, electroencephalogram results, blood alcohol concentrations, urine drug screens, and adequate documentation. We excluded patients with alcohol withdrawal, anoxic brain injury, subtherapeutic concentrations of other antiepileptics, hypoglycemia, and pseudoseizures. Primary outcomes of interest included cessation of active seizures or the prevention of seizure recurrence. We assessed safety by the presence or absence of adverse drug effects (ADE) attributed to the administration of LEV.
RESULTS: Thirty-four patients met inclusion and exclusion criteria. Half of the study cohort (17) presented with generalized tonic-clonic seizures (TCS); half (17) presented in generalized convulsive status epilepticus (GCSE). Six patients in GCSE received LEV during their seizures; 2 also received fosphenytoin. One improved immediately following LEV administration, and the remaining 5 had seizure control. Eleven GCSE patients (65%) remained seizure free after LEV therapy. The patients with TCS (17) received LEV after seizure(s) control. Sixteen (94%) were seizure-free during their hospital course. We found no adverse drug effects. In total, 27 of 34 patients (79%) had a return to baseline neurological and physical health. Six had long-term sequelae; none of which are known LEV side-effects. We identified 46 toxic substances and 22 known seizurogenic agents (48%). The median length of stay was 3.7 days (0.4-96), and the median duration of in-hospital LEV therapy was 1.6 days (0-49).
CONCLUSIONS: Levetiracetam used as a second-line agent was associated with control of drug-induced seizures and prevention of seizure recurrence without obvious adverse effects. A prospective study is needed to confirm these results.
参考来源
- Lee T, Warrick BJ, Sarangarm P, et al. Levetiracetam in toxic seizures. Clin Toxicol (Phila). 2017. PMID: 28753046. doi:10.1080/15563650.2017.1355056
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。